Skip to main content

Advertisement

SpringerLink
Log in

Non-alcoholic Fatty Liver Disease in Non-obese Patients

  • Fatty Liver Disease (S Harrison and J George, Section Editors)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Non-alcoholic fatty liver disease has quickly become the most common cause of liver disease. Interestingly, a cohort of patients has been identified with NAFLD who are of a normal body mass index. This review focuses on the current understanding of NAFLD among non-obese individuals.

Recent Findings

Advances in understanding the risk factors for non-obese non-alcoholic fatty liver disease and its link to visceral adiposity have increased our knowledge of this disease. Also, preliminary data notes an association with alterations in the gut microbiota and the effect of dietary habits on fatty liver disease in the non-obese population.

Summary

Non-obese NAFLD is a pervasive and likely underdiagnosed entity that seems to have similar risk factors and characteristics to fatty liver disease in the obese population. Still, non-obese NAFLD remains poorly understood.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most commons causes of chronic liver diseases in the United States from 1998 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524–30. https://doi.org/10.1016/j.cgh.2011.03.020.

    Article  PubMed  Google Scholar 

  2. Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One. 2017;12(3):e0173499. https://doi.org/10.1371/journal.pone.0173499.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Benedict M, Zhang X. Non-alcoholic fatty liver disease: an expanded review. World J Hepatol. 2017;9(16):715–32. https://doi.org/10.4254/wjh.v9.i16.715.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, national health and nutrition examination survey, 1988-2012. Prev Chronic Dis. 2017;14:E24. https://doi.org/10.5888/pcd14.160287.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Armstrong MJ, Houlihan DD, Newsome PN. NAFLD is underrecognized in the primary care setting: UK experience. Am J Gastroenterol. 109(9):1500–1. https://doi.org/10.1038/ajg.2014.207.

  6. Blais P, Husain N, Kramer JR, Kowalkowski M, El-Serag H, Kanwal F. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroentrerol. 2015;110(1):10–4. https://doi.org/10.1038/ajg.2014.134.

    Article  CAS  Google Scholar 

  7. Younossi ZM, Blissett D, Blissett R, Henry L, Setpanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577–86. https://doi.org/10.1002/hep.28785.

    Article  PubMed  Google Scholar 

  8. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–609. https://doi.org/10.1053/j.gastro.2012.04.001.

    Article  PubMed  Google Scholar 

  9. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.

    Article  PubMed  Google Scholar 

  10. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.

    Article  PubMed  Google Scholar 

  11. Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56(5):1751–9. https://doi.org/10.1002/hep.25889.

    Article  PubMed  Google Scholar 

  12. Adams LA, Lymp JF, St Sauver J, Ssanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population based cohort study. Gastroenterology. 2005;129(1):113–21.

    Article  PubMed  Google Scholar 

  13. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmgvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865–73.

    Article  CAS  PubMed  Google Scholar 

  14. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with non-alcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–97. https://doi.org/10.1053/j.gastro.2015.04.043.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51(2):595–602. https://doi.org/10.1002/hep.23314.

    Article  PubMed  Google Scholar 

  16. Margariti A, Deutsch M, Manolakopoulos S, Tiniakos D, Papatheodoridis GV. The severity of histologic liver lesions is independent of body mass index in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol. 2013;47(3):280–6. https://doi.org/10.1097/MCG.0b013e31826be328.

    PubMed  Google Scholar 

  17. Vos B, Moreno C, Nagy N, Fery F, Cnop M, Vereerstraeten P, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastroenterol Belg. 2011;74(3):389–94.

    PubMed  Google Scholar 

  18. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.

    Article  PubMed  Google Scholar 

  19. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med. 2004;164(19):2169–75.

    Article  PubMed  Google Scholar 

  20. Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol. 2006;40(8):745–52.

    Article  CAS  PubMed  Google Scholar 

  21. Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol. 2013;108(8):1299–304. https://doi.org/10.1038/ajg.2013.104.

    Article  PubMed  Google Scholar 

  22. Cho HC. Prevalence and factors associated with nonalcoholic fatty liver disease in a nonobese Korean population. Gut Liver. 2016;10(1):117–25. https://doi.org/10.5009/gnl14444.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Sinn DH, Gwak GY, Park HN, Kim JE, Min YW, Kim KM, et al. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. Am J Gastrenterol. 2012;107(4):561–7. https://doi.org/10.1038/ajg.2011.400.

    Article  Google Scholar 

  24. Kumar R, Rastogi A, Sharma MK, Bhatia V, Garg H, Bihari C, et al. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: do they differ from obese or overweight non-alcoholic fatty liver disease? Indian J Endocrinol Metab. 2013;17(4):655–71. https://doi.org/10.4103/2230-8210.113758.

    Article  Google Scholar 

  25. Bhat G, Baba CS, Pandey A, Kumari N, Choudhuri G. Insulin resistance and metabolic syndrome in nonobese Indian patients with non-alcoholic fatty liver disease. Trop Gastroenterol. 2013;34(1):18–24.

    Article  PubMed  Google Scholar 

  26. Margariti E, Deutsch M, Manolakopoulos S, Papatheodoridis GV. Non-alcoholic fatty liver disease may develop in individuals with normal body mass index. Ann Gastroenterol. 2012;25(1):45–51.

    PubMed  PubMed Central  Google Scholar 

  27. Akyuz U, Yesil A, Yilmaz Y. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels. Scand J Gastroenterol. 2015;50(3):341–6. https://doi.org/10.3109/00365521.2014.983160.

    Article  CAS  PubMed  Google Scholar 

  28. Lankarani KB, Ghaffarpasand F, Mahmoodi M, Lofti M, Zamiri N, Heydari ST, et al. Non alcoholic fatty liver disease in southern Iran: a population based study. Hepat Mon. 2013;13(5):e9248. https://doi.org/10.5812/hepatmon.9248.

    PubMed  PubMed Central  Google Scholar 

  29. •• Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012;91(6):319–27. https://doi.org/10.1097/MD.0b013e3182779d49. Prevalence and risk factors for non-obese NAFLD in North America.

    Article  Google Scholar 

  30. Aneni EC, Oni ET, Martin SS, Blaha MJ, Agatston AS, Feldman T, et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015;33(6):1207–14. https://doi.org/10.1097/HJH.0000000000000532.

    Article  CAS  PubMed  Google Scholar 

  31. Physical status: the use and interpretation of anthropometry. Report of a WHO expert Committee. World Health Organ Tech Rep Ser. 1995;854:1–452.

  32. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–63.

    Article  Google Scholar 

  33. Stefan N, Schick F, Haring HU. Causes, characteristics, and consequences of metabolically unhealthy normal weight humans. Cell Metab. 2017;26(2):292–300. https://doi.org/10.1016/j.cmet.2017.07.008.

    Article  CAS  PubMed  Google Scholar 

  34. Boyko EJ, Fujimoto WY, Leonetti DL, Newel-Morris L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care. 2000;23(4):465–71.

    Article  CAS  PubMed  Google Scholar 

  35. Despres JP, Lemieux S, Lemarche B, Prud’homme D, Moorjani S, Brun LD, et al. The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Int J Obes Relat Metabl Disord. 1995;19(Suppl 1):S76–86.

    Google Scholar 

  36. Lee SW, Son JY, Kim JM, Hwang SS, Han JS, Heo JN. Body fat distribution is more predictive of all-cause mortality than overall adiposity. Diabetes Obes Metab. 2017:July3; https://doi.org/10.1111/dom.13050.

  37. Naboush A, Hamdy O. Measuring visceral and hepatic fat in clinical practice and clinical research. Endocr Pract. 2013;19(4):587–9. https://doi.org/10.4158/EP12331.OR.

    Article  PubMed  Google Scholar 

  38. Swainson MG, Batterham AM, Tsakirides C, Rutherford ZH, Hind K. Prediction of whole-body fat percentage and visceral adipose tissue mass from five anthropometric variables. PLoS One. 2017;12(5):e0177175. https://doi.org/10.1371/journal.pone.0177175.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Shaikh S, Jones-Smith J, Schulze K, Ali H, Christian P, Shamim AA, et al. Excessive adiposity at low BMI levels among women in rural Bangladesh. J Nutr Sci. 2016;5:e11. https://doi.org/10.1017/jns.2015.32.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Misra A, Anoop S, Gulati S, Mani K, Bhatt SP, Pandey RM. Body fat patterning, hepatic fat and pancreatic volume of non-obese Asian Indians with type 2 diabetes in north India: a case-control study. PLoS One. 2015;10(10):e0140447. https://doi.org/10.1371/journal.pone.0140447.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. • Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, et al. Liver and cardiovascular damage in patients with lean non-alcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol. 2017; https://doi.org/10.1016/j.cgh.2017.04.045. Visceral adiposity rather than BMI correlates with NAFLD and features of MetS.

  42. Ha Y, Seo N, Shim JH, Kim SY, Park JA, Han S, et al. Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: a case-control study. J Gastroenterol Hepatol. 2015;30(11):1666–72. https://doi.org/10.1111/jgh.12996.

    Article  CAS  PubMed  Google Scholar 

  43. Sookoian S, Pirola CJ. PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease. World J Gastroenterol. 2012;18(42):6018–26. https://doi.org/10.3748/wjg.v18.i42.6018.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Severson TJ, Besur S, Bonkovsky HL. Genetic factors that affect nonalcoholic fatty liver disease: a systematic clinical review. World J Gastroenterol. 2016;22(29):6742–56. https://doi.org/10.3748/wjg.v22.i29.6742.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Smagris E, BasuRay S, Li J, Huang Y, Lai KM, Gromada J, et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology. 2015;61(1):108–18. https://doi.org/10.1002/hep.27242.

    Article  CAS  PubMed  Google Scholar 

  46. Romeo S, Kozlitina J, Xing C, Persemlidis A, Cox D, Pennacchio LA, et al. Genetic variation of PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461–5. https://doi.org/10.1038/ng.257.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Shen J, Wong GL, Chan HL, Chan HY, Yeung DK, Chan RS, et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther. 2014;39(5):532–9. https://doi.org/10.1111/apt.12609.

    Article  CAS  PubMed  Google Scholar 

  48. •• Feldman A, Eder SK, Felder TK, Kedenko L, Paulweber B, Stadlmayr A, et al. Clinical and metabolic characterization of lean Caucasian subjects with non-alcoholic fatty liver disease. Am J Gastroenterol. 2017;112(1):102–10. https://doi.org/10.1038/ajg.2016.318. Carrier rates of gene mutations between obese and non-obese NAFLD.

    Article  PubMed  Google Scholar 

  49. Iglesias A, Arranz M, Alvarez JJ, Perales J, Villar J, Herrera E, et al. Cholesteryl ester transfer protein in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids. Clin Chim Acta. 1996;248(2):157–74.

    Article  CAS  PubMed  Google Scholar 

  50. Shinkai H. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vasc Health Risk Manag. 2012;8:323–31. https://doi.org/10.2147/VHRM.S25238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Lin S, Dai R, Lin R. A meta-analytic evaluation of cholesteryl ester transfer protein (CETP) C-629A polymorphism in association with coronary heart disease risk and lipid changes. Oncotarget. 2017;8(2):2153–63. 10.18632/oncotarget.12898.

    PubMed  Google Scholar 

  52. Adams LA, Marsh JA, Ayonrinde OT, Olynyk KJ, Ang WQ, Beilin LJ, et al. Cholesteryl ester transfer protein gene polymorphisms increase the risk for fatty liver in females independent of adiposity. J Gastroenterol Hepatol. 2012;27(9):1520–7. https://doi.org/10.1111/j.1440-1746.2012.07120.x.

    Article  CAS  PubMed  Google Scholar 

  53. Liaw YW, Yin CY, Lai YS, Yang TC, Wang CJ, Whang-Peng J, et al. A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit. PLoS One. 2014;9(12):e111529. https://doi.org/10.1371/journal.pone.0111529.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  54. Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and cardiovascular outcomes in high-risk disease. N Engl J Med. 2017;376(20):1933–42. https://doi.org/10.1056/NEJMoa1609581.

    Article  PubMed  Google Scholar 

  55. Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol. 2012;28(2):159–65. https://doi.org/10.1097/MOG.0b013e32834e7b4b.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Noga AA, Zhao Y, Vance DE. An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins. J Biol Chem. 2002;277(44):42358–65.

    Article  CAS  PubMed  Google Scholar 

  57. Song J, da Costa KA, Fischer LM, Kohlmeier M, Kwock L, Wang S, et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J. 2005;19(10):1266–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Nakatsuka A, Matsuyama M, Yamaguchi S, Katayama A, Eguchi J, Murakami K, et al. Insufficiency of phosphatidylethanolamine N-methyltransferase is risk for lean non-alcoholic steatohepatitis. Sci Rep. 2016;6:21721. https://doi.org/10.1038/srep21721.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Kanwar P, Nelson JE, Yates K, Kleiner DE, Unalp-Arida A, Kowdley KV. Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastroenterol. 2016;3(1):e000114.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Nakahara T, Hyogo H, Yoneda M, Sumida Y, Eguchi Y, Fugii H, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014;49(11):1477–84. https://doi.org/10.1007/s00535-013-0911-1.

    Article  CAS  PubMed  Google Scholar 

  61. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104(4):861–7. https://doi.org/10.1038/ajg.2009.67.

    Article  PubMed  Google Scholar 

  62. Feldman A, Eder SK, Felder TK, Kedenko L, Paulweber B, Stadlmayr A, et al. Clinical and metabolic characterization of lean Caucasian subjects with non-alcoholic fatty liver disease. Am J Gastroenterol. 2017;112(1):102–10. https://doi.org/10.1038/ajg.2016.318.

    Article  PubMed  Google Scholar 

  63. •• Sookoian S, Pirola CJ. Systematic review and meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese subjects. Aliment Pharmacol Ther. 2017;46(2):85–95. https://doi.org/10.1111/apt.14112. Meta-analysis summarizing risk factors for NAFLD among both obese and non-obese populations.

    Article  CAS  PubMed  Google Scholar 

  64. Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Transl Res. 2017;183:57–70. https://doi.org/10.1016/j.trsl.2017.01.001.

    Article  CAS  PubMed  Google Scholar 

  65. Di Costanzo A, D’Erasmo L, Polimeni L, Baratta F, Coletta P, Di Martino M, et al. Non-alcoholic fatty liver disease and subclinical atherosclerosis: a comparison of metabolically-versus genetically-driven excess fat hepatic storage. Atherosclerosis. 2017;257:232–9. https://doi.org/10.1016/j.atherosclerosis.2016.12.018.

    Article  PubMed  CAS  Google Scholar 

  66. Danaei G, Lawes CM, Vander Hoorn S, Murray CJ, Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet. 2006;368(9548):1651–9.

    Article  PubMed  Google Scholar 

  67. Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity, and exercise. J Hepatol. 2017;S0168-8278(17):32052–4. https://doi.org/10.1016/j.jhep.2017.05.016.

    Google Scholar 

  68. Omagari K, Kato S, Tsuneyama K, Inohara C, Kuroda Y, Tsukuda H, et al. Effects of a long-term high-fat diet and switching from a high-fat to low-fat, standard diet on hepatic fat accumulation in Sprague-Dawley rats. Dig Dis Sci. 2008;53(12):3206–12. https://doi.org/10.1007/s10620-008-0303-1.

    Article  CAS  PubMed  Google Scholar 

  69. Ferramosca A, Zara V. Modulation of hepatic steatosis by dietary fatty acids. World J Gastroenterol. 2014;20(7):1746–55. https://doi.org/10.3748/wjg.v20.i7.1746.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Kainuma M, Fujimoto M, Sekiya N, Tsuneyama K, Cheng C, Takano Y, et al. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol. 2006;41(10):971–80. https://doi.org/10.1007/s00535-006-1883-1.

    Article  CAS  PubMed  Google Scholar 

  71. Abid A, Taha O, Nseir W, Farah R, Grosovski M, Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol. 2009;51(5):918–24. https://doi.org/10.1016/j.jhep.2009.05.033.

    Article  CAS  PubMed  Google Scholar 

  72. Assy N, Nasser G, Kamayse I, Nseir W, Beniashvili Z, Djibre A, et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol. 2008;22(10):811–6.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Moore JB, Gunn PJ, Fielding BA. The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease. Nutrients. 2014;6(12):5679–703. https://doi.org/10.3390/nu6125679.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Kontou M, Weidemann W, Bork K, Horstkorte R. Beyond glycosylation: sialic acid precursors act as signaling molecules and are involved in cellular control of differentiation of PC12 cells. Biol Chem. 2009;390(7):575–9. https://doi.org/10.1515/BC.2009.058.

    Article  CAS  PubMed  Google Scholar 

  75. Schauer R. Achievements and challenges of sialic acid research. Glycoconj J. 2000;17(7–9):485–99.

    Article  CAS  PubMed  Google Scholar 

  76. Bauer J, Osborn HM. Sialic acids in biological and therapeutic processes: opportunities and challenges. Future Med Chem. 2015;7(16):2285–99. https://doi.org/10.4155/fmc.15.135.

    Article  CAS  PubMed  Google Scholar 

  77. Manhardt CT, Punch PR, Dougher CWL, Lau JTY. Extrinsic sialylation is dynamically regulated by systemic triggers in vivo. J Biol Chem. 2017 Advance online publication; https://doi.org/10.1074/jbc.C117.795138.

  78. Browning LM, Jebb SA, Mishra GD, Cooke JH, O’Connell MA, Crook MA, et al. Elevated sialic acid, but not CRP, predicts features of the metabolic syndrome independently of BMI in women. Int J Obes Relat Metab Disord. 2004;28(8):1004–10.

    Article  CAS  PubMed  Google Scholar 

  79. Rajappa M, Ikkruthi S, Nandeesha H, Satheesh S, Sundar I, Ananthanarayanan PH, et al. Relationship of raised serum total and protein bound sialic acid levels with hyperinsulinemia and indices of insulin sensitivity and insulin resistance in non-diabetic normotensive obese subjects. Diabetes Metab Syndr. 2013;7(1):17–9. https://doi.org/10.1016/j.dsx.2013.02.030.

    Article  PubMed  Google Scholar 

  80. Tomino Y, Yagame M, Nomoto Y, Sakai H, Ito K, Nagaoka K, et al. Measurement of sialic acid and acute phase reactant proteins in sera of patients with diabetic nephropathy. J Diabet Complicat. 1988;2(4):175–8.

    Article  CAS  Google Scholar 

  81. Tseke P, Grapsa E, Stamatelopoulos K, Samouilidou E, Rammos G, Papamichael C, et al. Correlations of sialic acid with markers of inflammation, atherosclerosis and cardiovascular events in hemodialysis patients. Blood Purif. 2008;26(3):261–6. https://doi.org/10.1159/000124850.

    Article  CAS  PubMed  Google Scholar 

  82. • Lu Z, Ma H, Xu C, Shao Z, Can C, Li Y. Serum sialic acid is significantly associated with nonalcoholic fatty liver disease in a nonobese Chinese population: a cross-sectional study. Biomed Res Int. 2016:5921589. https://doi.org/10.1155/2016/5921589. Correlation of elevated sialic acid with non-obese NAFLD.

  83. Lu Z, Ma H, Xu C, Shao Z, Cen C, Li Y. Serum sialic acid level is significantly associated with nonalcoholic fatty liver disease in a nonobese Chinese population: a cross-sectional study. Biomed Res Int. 2016:5921589. https://doi.org/10.1155/2016/5921589.

  84. Ibrahim MA, Abdulkadir A, Onojah A, Sani L, Adamu A, Abdullahi H. Modulation of sialic acid levels among some organs during insulin resistance or hyperglycemic states. Mol Cell Biochem. 2016;41(1):235–9. https://doi.org/10.1007/s11010-015-2585-x.

    Article  CAS  Google Scholar 

  85. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533. https://doi.org/10.1371/journal.pbio.1002533.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  86. Wang M, Monaco MH, Donovan SM. Impact of early gut microbiota on immune and metabolic development and function. Semin Fetal Neonatal Med. 2016;21(6):380–7. https://doi.org/10.1016/j.siny.2016.04.004.

    Article  PubMed  Google Scholar 

  87. Thaiss CA, Zmora N, Levy M, Elinay E. The microbiome and innate immunity. Nature. 2016;535(7610):65–74. https://doi.org/10.1038/nature18847.

    Article  CAS  PubMed  Google Scholar 

  88. LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol. 2013;24(2):160–8. https://doi.org/10.1016/j.copbio.2012.08.005.

    Article  CAS  PubMed  Google Scholar 

  89. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 2017: Apr 9; https://doi.org/10.1007/s00394-017-1445-8.

  90. Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412–25. https://doi.org/10.1038/nrgastro.2016.85.

    Article  CAS  PubMed  Google Scholar 

  91. The Human Microbiome Project Consortium. Structure, function, and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–14. https://doi.org/10.1038/nature11234.

    Article  PubMed Central  CAS  Google Scholar 

  92. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480–4. https://doi.org/10.1038/nature07540.

    Article  CAS  PubMed  Google Scholar 

  93. Backhed F, Ding H, Want T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  94. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022–3.

    Article  CAS  PubMed  Google Scholar 

  95. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601–9. https://doi.org/10.1002/hep.26093.

    Article  CAS  PubMed  Google Scholar 

  96. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58(1):120–7. https://doi.org/10.1002/hep.26319.

    Article  CAS  PubMed  Google Scholar 

  97. • Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci Rep. 2016;6:32002. https://doi.org/10.1038/srep32002. Fecal microbiota alterations in non-obese NAFLD.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013;62(12):1787–94. https://doi.org/10.1136/gutjnl-2012-303816.

    Article  PubMed  CAS  Google Scholar 

  99. Mokhtari Z, Gibson DL, Hekmatdoost A. Nonalcoholic fatty liver disease, the gut microbiome, and diet. Adv Nutr. 2017;8(2):240–52.

    Article  PubMed  Google Scholar 

  100. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091–103. https://doi.org/10.1136/gut.2008.165886.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Schwiertz A, Taras D, Schafer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010;18(1):190–5. https://doi.org/10.1038/oby.2009.167.

    Article  Google Scholar 

  102. Layden BT, Angueira AR, Brodsky M, Durai V, Lowe WL Jr. Short chain fatty acids and their receptors: new metabolic targets. Transl Res. 2013;161(3):131–40. https://doi.org/10.1016/j.trsl.2012.10.007.

    Article  CAS  PubMed  Google Scholar 

  103. Mofidi F, Poustchi J, Yari Z, Nourinayyer B, Merat S, Sharafkhah M, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomized double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017;117(5):662–8. https://doi.org/10.1017/S0007114517000204.

    Article  CAS  PubMed  Google Scholar 

  104. Gao X, Zhu Y, Wen Y, Liu G, Wan C. Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: a meta-analysis of randomized controlled trials. Hepatol Res. 2016;46(12):1226–33. https://doi.org/10.1111/hepr.12671.

    Article  CAS  PubMed  Google Scholar 

  105. Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013;12(2):256–62.

    CAS  PubMed  Google Scholar 

  106. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15(9):1090–5.

    CAS  PubMed  Google Scholar 

  107. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012;57(2):545–53. https://doi.org/10.1007/s10620-011-1887-4.

    Article  PubMed  Google Scholar 

  108. Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. Metabolism. 2017;71:17–32. https://doi.org/10.1016/j.metabol.2017.02.014.

    Article  CAS  PubMed  Google Scholar 

  109. Portillo-Sanchez P, Cusi K. Treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus. Clin Diabetes Endocrinol. 2016;2:9. https://doi.org/10.1186/s40842-016-0027-7.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Oh S, So R, Shida T, Matsuo T, Kim B, Akiyama K, et al. High-intensity aerobic exercise improves both hepatic fat content and stiffness in sedentary obese men with nonalcoholic fatty liver disease. Sci Rep. 2017;7:43029. https://doi.org/10.1038/srep43029.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60(9):1278–83. https://doi.org/10.1136/gut.2011.242073.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85. https://doi.org/10.1056/NEJMoa0907929.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, et al. Long-term pioglitazone for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165(5):305–15. https://doi.org/10.7326/M15-1774.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Virginia Commonwealth University, West Hospital, 14th Floor, 1200 E. Broad St., MCV Box 980342, Richmond, VA, 23298-0342, USA

    Christopher J. Schmoyer & Mohammad S. Siddiqui

Authors
  1. Christopher J. Schmoyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammad S. Siddiqui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad S. Siddiqui.

Ethics declarations

Conflict of Interest

Christopher J. Schmoyer and Mohammad S. Siddiqui each declare no potential conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Fatty Liver Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schmoyer, C.J., Siddiqui, M.S. Non-alcoholic Fatty Liver Disease in Non-obese Patients. Curr Hepatology Rep 16, 382–390 (2017). https://doi.org/10.1007/s11901-017-0377-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-017-0377-3

Keywords

Search

Navigation